Istituto Auxologico Italiano
Milan, MI, 20145, Italy
Location status: Recruiting
NCT Number: NCT05766098
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.
Interested in participating?
Request InfoAll sexes
Observational
Milan, MI, 20145, Italy
Location status: Recruiting
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Characterization of genetic profile of tumor tissues
Time frame: years 1-8
The mutational profile of about 600 PTCs will be characterized and correlate with the clinical characteristics and patient outcomes
Contact information is provided by the study sponsor or research team.
Istituto Auxologico Italiano
Other
Caratterizzazione Del Profilo Mutazionale Nel Tumore Papillare Della Tiroide Tramite Tecnologia Mass-ARRAY
Acronym: PTC-ARRAY
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00001160
Adenocarcinoma, Adenocarcinoma, Follicular
Bethesda, Maryland, United States
View Trial DetailsNCT06316895
Adenocarcinoma, Adenocarcinoma, Papillary
Beijing, China
View Trial DetailsNCT07140757
Adenocarcinoma, Adenocarcinoma, Papillary
Houston, Texas, United States
View Trial DetailsNCT06133374
Adenocarcinoma, Adenocarcinoma, Papillary
Calgary, Alberta, Canada
View Trial Details